… be willing to take a GLP-1 pill. Doustdar estimated that … Eli Lilly.” — Jonathan Gardner Renewed IPO optimism  Less than a dozen … Metsera, was acquired by Pfizer. IPOs, then, could rebound in the … , though there could be IPO opportunities for a handful of …

… in time for JPM, the IPO window cracked open, with Aktis … from the labels of certain GLP-1 medications after a comprehensive …

… ;entering a more discerning IPO marketplace where drug innovators … said. Still, he continued, IPOs will remain a crucial part … , days before announcing its IPO, injectable MET-097 again … differently than the commonly-exploited GLP-1 pathway. After aligning …

… peptide-1 (GLP-1) agonist receptors, Medicare Advantage, digital health IPOs, and … of the year. For example, GLP-1 receptor agonists will continue …

Saxo 'predicts' GLP-1 weightloss drugs for pets … weight loss therapies in which GLP-1 treatments are targeted at … publicly, resulting in the largest IPO valuation in history and igniting …

… Omada Health's successful IPOs; both companies are tech- … a given category, such as GLP-1 management, and test them … talks with bankers about potential IPOs. Still, no reports have … of momentum pent up around IPO readiness at the organizational level …

… completed a $5.12 million initial public offering in early February 2025 and … of the stock before the IPO and still hold a large … after the exploding market for GLP-1 weight-loss and diabetes …

… of InnovationRx, Medline’s blockbuster IPO, Fred Moll’s surgical robotics … Medical supplies giant Medline’s IPO is set to be this … it’s bringing in from GLP-1 drugs Zepbound and Mounjaro …

Investors hoping for a sweet treat were left with mild disappointment this week as the debut of the newly independent Magnum Ice Cream Co. (NYSE:MICC) was less than impressive.  Magnum is the world's largest ice cream maker and home to heavy hitters …

… announced the pricing of its initial public offering (the “Offering”) of 3,750 … FDA-required good laboratory practice (“GLP”) toxicology and pharmacokinetic studies for …